Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.26
MNKD's Cash-to-Debt is ranked lower than
92% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. MNKD: 0.26 )
Ranked among companies with meaningful Cash-to-Debt only.
MNKD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.29 Max: No Debt
Current: 0.26
Equity-to-Asset -2.79
MNKD's Equity-to-Asset is ranked lower than
99% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MNKD: -2.79 )
Ranked among companies with meaningful Equity-to-Asset only.
MNKD' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.79  Med: -1.06 Max: 0.87
Current: -2.79
-2.79
0.87
Debt-to-Equity -0.75
MNKD's Debt-to-Equity is ranked lower than
99.99% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. MNKD: -0.75 )
Ranked among companies with meaningful Debt-to-Equity only.
MNKD' s Debt-to-Equity Range Over the Past 10 Years
Min: -109.2  Med: -1.57 Max: 9.93
Current: -0.75
-109.2
9.93
Debt-to-EBITDA 1.11
MNKD's Debt-to-EBITDA is ranked higher than
67% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. MNKD: 1.11 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MNKD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.9  Med: -1.43 Max: 1.11
Current: 1.11
-2.9
1.11
Interest Coverage 3.63
MNKD's Interest Coverage is ranked lower than
93% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MNKD: 3.63 )
Ranked among companies with meaningful Interest Coverage only.
MNKD' s Interest Coverage Range Over the Past 10 Years
Min: 3.63  Med: 3.64 Max: 3.64
Current: 3.63
3.63
3.64
Piotroski F-Score: 4
Altman Z-Score: -40.61
Beneish M-Score: 4587.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 30.69
MNKD's Operating Margin % is ranked higher than
93% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. MNKD: 30.69 )
Ranked among companies with meaningful Operating Margin % only.
MNKD' s Operating Margin % Range Over the Past 10 Years
Min: -3073570  Med: -350481.86 Max: 38.49
Current: 30.69
-3073570
38.49
Net Margin % 71.60
MNKD's Net Margin % is ranked higher than
98% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. MNKD: 71.60 )
Ranked among companies with meaningful Net Margin % only.
MNKD' s Net Margin % Range Over the Past 10 Years
Min: -2931900  Med: -402755.43 Max: 71.91
Current: 71.6
-2931900
71.91
ROA % 127.01
MNKD's ROA % is ranked higher than
99% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. MNKD: 127.01 )
Ranked among companies with meaningful ROA % only.
MNKD' s ROA % Range Over the Past 10 Years
Min: -141.48  Med: -70.42 Max: 127.01
Current: 127.01
-141.48
127.01
ROC (Joel Greenblatt) % 337.37
MNKD's ROC (Joel Greenblatt) % is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. MNKD: 337.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MNKD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -285.89  Med: -95.4 Max: 337.37
Current: 337.37
-285.89
337.37
GuruFocus has detected 4 Warning Signs with MannKind Corp MNKD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MNKD's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

MNKD Guru Trades in Q3 2016

Paul Tudor Jones 103,325 sh (unchged)
» More
Q4 2016

MNKD Guru Trades in Q4 2016

Joel Greenblatt 90,068 sh (New)
Paul Tudor Jones 103,325 sh (unchged)
» More
Q1 2017

MNKD Guru Trades in Q1 2017

Joel Greenblatt 18,825 sh (+4.50%)
Paul Tudor Jones 20,665 sh (unchged)
» More
Q2 2017

MNKD Guru Trades in Q2 2017

Paul Tudor Jones 20,665 sh (unchged)
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:MNKD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Sold Out $0.71 - $1.65 $ 4.11219%0
Joel Greenblatt 2017-03-31 Add 4.50%$1.48 - $3.56 $ 4.1156%18,825
Joel Greenblatt 2016-12-31 New Buy$2.09 - $3.95 $ 4.1142%18,014
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:TPE:1720, NAS:SBPH, OSTO:MVIR B, ROCO:6492, XTAE:KMDA, TSX:ZYME, LSE:VRP, TSE:2395, NAS:OCUL, NAS:MACK, LSE:TRX, NAS:CGEN, NAS:VTVT, NAS:ALRN, ROCO:6617, XKRX:053030, NAS:VSTM, XKRX:019175, NAS:ADXS, NAS:ALBO » details
Traded in other countries:NNFN.Germany, MNKD.Israel,
Headquarter Location:USA
MannKind Corp is a development stage biotech firm. It is engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and cancer.

MannKind is a biotech firm focused on researching treatments for diabetes and cancer. Its lead product candidate, Afrezza, is a rapid-acting inhaled insulin that has been approved in the U.S. and partnered with Sanofi for global commercialization. MannKind's early-stage pipeline includes testing its proprietary inhalation technology in other diabetes treatments and developing several early-stage immunotherapy and oncology therapeutics.

Ratios

vs
industry
vs
history
PE Ratio 3.06
MNKD's PE Ratio is ranked higher than
96% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. MNKD: 3.06 )
Ranked among companies with meaningful PE Ratio only.
MNKD' s PE Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.4 Max: 3.94
Current: 3.06
0.59
3.94
PE Ratio without NRI 3.06
MNKD's PE Ratio without NRI is ranked higher than
97% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. MNKD: 3.06 )
Ranked among companies with meaningful PE Ratio without NRI only.
MNKD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.59  Med: 1.4 Max: 3.94
Current: 3.06
0.59
3.94
Price-to-Owner-Earnings 22.09
MNKD's Price-to-Owner-Earnings is ranked higher than
85% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. MNKD: 22.09 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MNKD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.72  Med: 7.17 Max: 28.39
Current: 22.09
2.72
28.39
PS Ratio 2.22
MNKD's PS Ratio is ranked higher than
94% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. MNKD: 2.22 )
Ranked among companies with meaningful PS Ratio only.
MNKD' s PS Ratio Range Over the Past 10 Years
Min: 0.43  Med: 15500 Max: 79400
Current: 2.22
0.43
79400
EV-to-EBIT 3.84
MNKD's EV-to-EBIT is ranked higher than
88% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. MNKD: 3.84 )
Ranked among companies with meaningful EV-to-EBIT only.
MNKD' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.5  Med: -3.7 Max: 4.5
Current: 3.84
-19.5
4.5
EV-to-EBITDA 3.74
MNKD's EV-to-EBITDA is ranked higher than
89% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. MNKD: 3.74 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNKD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.3  Med: -4.1 Max: 4.4
Current: 3.74
-21.3
4.4
EV-to-Revenue 3.09
MNKD's EV-to-Revenue is ranked higher than
90% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. MNKD: 3.09 )
Ranked among companies with meaningful EV-to-Revenue only.
MNKD' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1  Med: 22748.7 Max: 91126.2
Current: 3.09
1.1
91126.2
Current Ratio 0.59
MNKD's Current Ratio is ranked lower than
93% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. MNKD: 0.59 )
Ranked among companies with meaningful Current Ratio only.
MNKD' s Current Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.31 Max: 12.24
Current: 0.59
0.12
12.24
Quick Ratio 0.56
MNKD's Quick Ratio is ranked lower than
91% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. MNKD: 0.56 )
Ranked among companies with meaningful Quick Ratio only.
MNKD' s Quick Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.31 Max: 12.24
Current: 0.56
0.12
12.24
Days Inventory 26.99
MNKD's Days Inventory is ranked higher than
85% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. MNKD: 26.99 )
Ranked among companies with meaningful Days Inventory only.
MNKD' s Days Inventory Range Over the Past 10 Years
Min: 8.49  Med: 17.88 Max: 27.26
Current: 26.99
8.49
27.26
Days Sales Outstanding 2.66
MNKD's Days Sales Outstanding is ranked higher than
94% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. MNKD: 2.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNKD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.66  Med: 4692.86 Max: 30331.5
Current: 2.66
2.66
30331.5
Days Payable 51.35
MNKD's Days Payable is ranked lower than
53% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. MNKD: 51.35 )
Ranked among companies with meaningful Days Payable only.
MNKD' s Days Payable Range Over the Past 10 Years
Min: 23.78  Med: 55.86 Max: 87.94
Current: 51.35
23.78
87.94

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.00
MNKD's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. MNKD: -9.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNKD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.3  Med: -39.35 Max: -8
Current: -9
-58.3
-8

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % 26.08
MNKD's Earnings Yield (Greenblatt) % is ranked higher than
97% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. MNKD: 26.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNKD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -527.6  Med: -19 Max: 80.6
Current: 26.08
-527.6
80.6

More Statistics

Revenue (TTM) (Mil) $179.93
EPS (TTM) $ 1.34
Beta2.67
Short Percentage of Float32.78%
52-Week Range $0.67 - 6.96
Shares Outstanding (Mil)104.71

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 13 33 58 120
EPS ($) -0.88 -0.73 -0.52 -0.24
EPS without NRI ($) -0.88 -0.73 -0.52 -0.24
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}